Table 1 Completed and current clinical trials evaluating the applicability of Oncolytic Viruses in lung cancer
From: Lung cancer immunotherapy: progress, pitfalls, and promises
Clinical Trial ID | Oncolytic virus | Virus type | Transgene/ Target | Combination | Cancer | Status | Duration | Sponsor/ Agency |
|---|---|---|---|---|---|---|---|---|
NCT 02,879,760 | Ad-MAGEA3 with MG1-MAGEA3 | Adenovirus vector Maraba virus | Melanoma associated antigen 3 | Pembrolizumab | NSCLC | Phase I / II | 2017–2020 | Turnstone Biologics, Corp |
NCT 02,043,665 | CVA21 | Coxsackie virus | None (CAVATAK) | Pembrolizumab | NSCLC | Phase I | 2013–2020 | Viralytics |
NCT 03,647,163 | VSV-IFNβ-NIS | Vesicular Stomatitis virus (VSV) | Interferon-beta (IFNβ) and the sodium iodide symporter (NIS) | Pembrolizumab | NSCLC | Phase I / II | 2019–2021 | Vyriad, Inc |
NCT 00,861,627 | REOLYSIN | Reovirus Serotype 3—Dearing Strain | KRAS/EGFR | Carboplatin Paclitaxel | NSCLC | Phase II | 2009–2015 | Oncolytics Biotech |
NCT 01,708,993 | REOLYSIN | Reovirus Serotype 3—Dearing Strain | KRAS/EGFR | Pemetrexed Docetaxel | NSCLC | Phase II | 2012–2016 | Canadian Cancer Trials Group |
NCT 01,017,601 | (NTX-010) Seneca Valley virus-001 | Seneca virus | NA | NA | SCLC | Phase II | 2010–2013 | Alliance for Clinical Trials in Oncology |
NCT 01,574,729 | rAd-p53 | Adenovirus | p53 | surgery | NSCLC | Phase II | 2012–2015 | Shenzhen SiBiono GeneTech Co.,Ltd |
NCT 03,004,183 | ADV/HSV-tk | Herpes simplex virus | thymidine kinase | SBRT Pembrolizumab | NSCLC | Phase II | 2017–2022 | The Methodist Hospital Research Institute |
NCT 02,831,933 | ADV/HSV-tk | Herpes simplex virus | thymidine kinase | SBRT Nivolumab | NSCLC | Phase II | 2017–2020 | Eric Bernicker, MD |